Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Liver Cancer|June 16, 2023
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular CarcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.
European Journal of Medicinal Chemistry|October 8, 2025
Lipophilic integrated bioorthogonal self-catalyzed nitric oxide donor-platinum(IV) prodrugs for enhanced antitumor efficacy against esophageal cancerZiyu Qian, Xun Yuan, Qing Zhao, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.
Acta Pharmaceutica Sinica. B|April 3, 2025
A novel anti-ischemic stroke candidate drug AAPB with dual effects of neuroprotection and cerebral blood flow improvementJianbing Wu, Duorui Ji, Weijie Jiao, et al.
Environmental Research|March 6, 2026
Environmental heat and cold stress, thyrotropin abnormalities, and reduced fecundability in 14 million Chinese couples: A nationwide preconception cohort studyXinghou He, Mengyao Li, Ying Yang, et al.
Liver Cancer|June 30, 2025
Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled TrialYan Zhao, Wei Bai, Rong Ding, et al.
Liver Cancer|July 11, 2020
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational StudyZhexuan Wang, Enxin Wang, Wei Bai, et al.
Liver Cancer|August 18, 2022
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective StudyDongdong Xia, Wei Bai, Enxin Wang, et al.
The Lancet. Oncology|June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 studyZhenggang Ren, Jianming Xu, Yuxian Bai, et al.
European Radiology|April 6, 2022
Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolizationDongdong Xia, Qiuhe Wang, Wei Bai, et al.
Pageof 14